Skip to main content
Premium Trial:

Request an Annual Quote

Raynard Kington, Guy Van Meter

Premium
Raynard Kington will step into the role of acting director of the National Institutes of Health on Friday, Oct. 31, after the departure of Elias Zerhouni, who announced in September that he plans to leave his post.
 
Zerhouni confirmed this week that he has tapped Kington to take over the post until a new director is appointed, which will happen sometime after the next administration settles into the White House.
 
Kington has served as Zerhouni’s deputy since 2003, and before that he was associate director of NIH for behavioral and social sciences research. He has also served as acting director of the National Institute on Alcohol Abuse and Alcoholism, and he worked at the National Center for Health Statistics.
 
Before his arrival at NIH, Kington was a senior scientist at the Rand Corporation, where he was co-director of the Drew/RAND Center on Health and Aging.
 

 
Guy Van Meter has joined Adimab as senior director, head of business development, the company announced last week.
 
Van Meter joins Adimab from Pfizer where he was involved in new business initiatives around RNAi therapeutics and regenerative medicine for Pfizer’s Biotherapeutics and Bioinnovation Center. Before that he was at Dyax where he also worked in business development.
 
Based in Lebanon, NH, Adimab is developing yeast-based antibodies.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.